Hemolytic anemia during 24 weeks of ribavirin and interferon-alpha2b combination therapy does not influence the cardiac function of patients with viral hepatitis C.
Sato
Shuichi
S
Furuta
Kouichiro
K
Miyake
Tatsuya
T
Mishiro
Tomoko
T
Kohge
Naruaki
N
Akagi
Shuji
S
Uchida
Yasushi
Y
Rumi
M A K
MA
Ishihara
Shunji
S
Adachi
Kyouichi
K
Kinoshita
Yoshikazu
Y
D000743:Anemia, Hemolytic / Q000139:chemically induced*; D004359:Drug Therapy, Combination; D005260:Female; D006454:Hemoglobins / Q000032:analysis / Q000187:drug effects; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D020097:Natriuretic Peptide, Brain / Q000097:blood* / Q000187:drug effects; D011994:Recombinant Proteins; D012254:Ribavirin / Q000009:adverse effects* / Q000627:therapeutic use
D006454:Hemoglobins; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D020097:Natriuretic Peptide, Brain; D012254:Ribavirin